KRAS and Noonan syndrome: Furthermore, LZTR1 loss-of-function mutations linked to Noonan syndrome and schwannomatosis underscore its critical role in maintaining RAS signaling homeostasis, providing a molecular rationale for therapeutic strategies targeting KRAS degradation [43].